New hope for Tough-to-Treat breast cancer: experimental drug trial shows promise

NCT ID NCT04072952

Summary

This clinical trial is testing a new drug called ARV-471, both by itself and combined with an existing drug (palbociclib), for people with a specific type of advanced breast cancer (ER+/HER2-). The main goals are to find safe doses and see if the treatment can shrink tumors or stop cancer growth in patients whose cancer has progressed despite prior hormone therapy and chemotherapy. The study involves about 217 adults whose cancer is no longer responding to standard curative options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinical Trial Site

    Palo Alto, California, 94304, United States

  • Clinical Trial Site

    San Francisco, California, 94158, United States

  • Clinical Trial Site

    Santa Monica, California, 90404, United States

  • Clinical Trial Site

    Norwalk, Connecticut, 06856, United States

  • Clinical Trial Site

    Fort Myers, Florida, 33901, United States

  • Clinical Trial Site

    Tampa, Florida, 33612, United States

  • Clinical Trial Site

    Chicago, Illinois, 60637, United States

  • Clinical Trial Site

    Boston, Massachusetts, 02114, United States

  • Clinical Trial Site

    Boston, Massachusetts, 02215, United States

  • Clinical Trial Site

    Ann Arbor, Michigan, 48109, United States

  • Clinical Trial Site

    St Louis, Missouri, 63110, United States

  • Clinical Trial Site

    East Brunswick, New Jersey, 08816, United States

  • Clinical Trial Site

    The Bronx, New York, 10461, United States

  • Clinical Trial Site

    Charlotte, North Carolina, 28204, United States

  • Clinical Trial Site

    Nashville, Tennessee, 37203, United States

  • Clinical Trial Site

    Seattle, Washington, 98109, United States

Conditions

Explore the condition pages connected to this study.